It is not the purpose of this paper to extensively review all aspects of blood transfusion, but rather to highlight some of the recent advances in blood transfusion, discuss problems associated with transfusion and to question the apparent benefits of blood transfusion in certain clinical situations. Because blood is obtained from human beings, many clinicians assume that it can only be beneficial and do not consider that it has a therapeutic index as with any other form of therapy.
Quality Control of Stored Blood Products
Although blood collection, fractionation and storage is highly sophisticated and efficient, the clinician should consider carefully what guarantee he actually has regarding the quality of the blood component he is administering to a patient. As already mentioned 70% red cell survival at 24 hours is regarded as acceptable, but some donor blood withstands storage poorly and post transfusion survival may be less. There is no guarantee regarding the life history of a unit of blood prior to its transfusion. A unit of blood may well be cross matched several times and not transfused. The blood may also have been transported between hospitals and within hospitals and had considerable periods of exposure to room temperature or incorrectly stored in non monitored refrigerators. It is a sobering thought to consider that blood is "dated" when unnecessarily cross matched and not transfused, and is finally given to a patient probably least able to cope with the potential complications of stored blood transfusion. Table 1 compares the haematological and biochemical features of blood stored for 14 days compared with normal. On storage, red cells become rigid spherocytes which will either succumb following transfusion or require approximately 24 hours to re-establish themselves as biconcave discs. Much has been written in recent years about the alteration in 2, 3 DPG levels on storage and changes in oxygen affinity of the haemoglobin molecule (International Forum 1978) . The significance of these changes is controversial (vide infra). Despite this, red cells remain the only commonly available "solution" which will restore the oxygen carrying capacity in exsanguinated patients. Apart from the red cells, the remaining contents of a unit of stored whole b;ood, with micro aggregates, altered plasma proteins and electrolytes can hardly be regarded as the ideal fluid for volume replacement. 
Fresh Whole Blood
As a result of advances in fractionation of donor blood into its various components, fewer transfusions are given in the form of whole blood. There has been a tendency in recent years, especially by haematologists, to denegrate the use of fresh whole blood. The argument has been put forward that all the individual components of blood can be obtained separately and used only when necessary. This rather simplistic approach implies that all the factors required for perfect oxygen transport, for controlling haemostasis (platelets, coagulation factors and coagulation inhibitors) and other less well understood functions of blood (? bacteriocidal activity) are as well preserved in the blood fractions as they are in freshly drawn whole blood which has not been refrigerated. As already pointed out, blood is a perishable commodity and changes occur in blood from the moment it leaves the donor's veins and enters the storage anticoagulant. The process of cooling whole blood or freezing plasma has deleterious effects, many of which are incompletely understood (Stormorken 1977) . Freshly collected, non refrigerated blood in plastic packs still remains the most effective way of obtaining all the components of blood which are needed in certain clinical situations (massive blood transfusion, prolonged cardiopulmonary by-pass, and gross haemostatic disturbances with blood loss). This is particularly so when the individual blood fractions are not immediately available (Sheldon et al. 1975 ). Microfilters should not b~ used in conjunction with fresh blood transfusions.
Use of fresh blood may not only be of advantage to the patient, but may also have logistic and psychological advantages. In the Intensive Care situation, or elective major surgery, donors (particularly relatives) may be cross matched in advance and venesected when necessary. This system has the advantage of avoiding prolonged in vitro storage of the blood and allowing relatives and friends to feel that they are making a significant contribution towards the patient's recovery.
Blood Transfusion to Improve Oxygen Carrying Capacity.
If blood is being transfused to elevate the patient's haemoglobin level, for the purpose of improving oxygen carrying capacity, the clinician must consider several factors to ensure that he does in fact achieve this end. The oxygen transport chain, from inspiration of ambient oxygen to the delivery and utilization of that oxygen at tissue level, is a remarkable system which has enormous reserve when oxygen requirement increases, but also an extraordinary capacity to compensate for gross defects at different points along the chain. Although most aspects of oxygen transport can b~ measured, the haemoglobin and its binding of oxygen are by far the simplest and most readily available. This has resulted in clinicians concentrating on this point in the oxygen transport chain, frequently to the detriment of others (e.g. P fiO , circulation and microcirculation). Physiologists have known for many years that maximum oxygen availability to the tissues at rest is achieved at a lower than normal haematocrit (30%) (Gruber 1977) . As the major determinant for tissue oxygenation is the rate of red cell flux through the microcirculation, factors which may impair the flow of red cells in the microcirculation must be considered. Increase in whole blood viscosity has been recognized to occur in association with elevation of acute and chronic phase reactants (Litwin 1976) , and the effects of this on the microcirculation have been hotly debated for decades (International Forum 1977) . Not only is there an increase in plasma viscosity in many disease states, but there may also be alterations in the red cells and haemoglobin function. Many workers feel that the fall in haemoglobin that occurs in association with the rise in whole blood viscosity is a compensatory mechanism to ensure that red cell flux through the microcirculation is not impaired. The viscosity of stored blood is increased (La Celle et al. 1971) and effects on whole blood viscosity of transfusing stored red cells into normovolaemic patients with haematocrits above 30% have not been adequately studied. Despite an increase in haemoglobin concentration the anticipated improvement in oxygen transport may be an illusion.
As well as changes in red cell shape and viscosity on storage, there are alterations in haemoglobin function. The clinical relevance of low 2, 3 DPG levels and high haemoglobin oxygen affinity of stored blood is unclear (Harken et al. 1976 , Harken 1977 , International Forum 1978 . There is no convincing human data available at the present time indicating that the transfusion of such blood is harmful. However there is good evidence in many congenital and acquired haematological disorders in which a shift in the oxygen dissociation curve is significant for oxygen transport. As well as providing a protein for carrying adequate amounts of oxygen to the tissues, the haemoglobin molecule also allows fine tuning of this system of oxygen delivery. It suffices to say that inadequate data is available at the present time to evaluate the advantages of transfusing normovolaemic patients, at rest, to a haematocrit much above 30%. Many of the disadvantages of such transfusion in terms of complications are well understood and should be weighed against the theoretical advantages of such red cell transfusions. 
Transfusion for Correction of Haemorrhagic Hypovolaemia
Man is unlikely to survive a loss of more than a third of his circulating blood volume. This is in marked contrast to the 75% loss he can sustain in haemoglobin oxygen carrying capacity, assuming normovolaemia and normal cardio-respiratory function is maintained. In massive blood loss situations, whatever blood or blood-products are available for maintaining both intravascular volume and oxygen carrying capacity should be used. The most practical and readily available being stored whole blood. There are as many opinions as there are solutions available for blood volume expansion. Most controversy revolves around the use of colloids versus crystalloids and the incidence of reactions to the various replacement fluids. It is not the purpose of this review to enter into this debate except to mention the plasma volume expanders which are available. Dried plasma and fresh frozen plasma have largely been replaced by pasteurized plasma protein fractions (e.g. stable plasma protein solution, 5% or 25% albumin solution) . These solutions have sustained volume expanding characteristics depending on albumin concentrations and the state of capillary permeability (SkilIman 1976).
Modified gelatins (e.g. HaemacceI), have been popular for initial resuscitation. Haemaccel has a very short half life (4t hours) and a 50% intravascular-extravascular distribution. These characteristics of the solution may be regarded as an advantage or disadvantage depending on ones point of view.
For initial urgent resuscitation, Haemaccel, if given in adequate amounts, is a good volume expander, however it must be remembered that the volume given is equivalent to normal saline after the gelatin has been cleared. This means that Haemaccel is only a temporary volume expander and many workers would see this as advantageous, as it allows "room" for the blood when it becomes available. The dextrans have also been used for many years as initial synthetic plasma volume expanders. Dextran 70 (Macrodex) is the solution usually used in Australia. Macrodex remains wholly within the circulation and has a greater volume expanding effect and longer half life (12 hours) than Haemaccel. Dextrans are also advocated by some workers because of their effects on red cell aggregability and anti thrombotic effect (Ulrich 1977) .
Stroma free haemoglobin solutions have been used experimentally to achieve both blood volume expansion and oxygen carrying capacity, but rapid renal clearance of haemoglobin reduces their efficacy (Sunder-Plassman 1975) . Attempts have been made to bind haemoglobin onto various substances in an effort to prolong the intravascular life of the haemoglobin but due to an extremely low PGO these methods have not been particularly successful (Greenberg et al. 1977) .
Platelet and Granulocyte Transfusions
The last decade has seen significant improvements in the methods for obtaining platelets and granulocytes from donors. The main impetus to progress has been the introduction of in vivo blood cell separators, allowing the collection of large numbers of these cellular components from a single donor. Consultation with a haematologist is the most appropriate action to take when platelets and granulocytes are considered necessary. It should be emphasized that patients presenting with severe thrombocytopenia or agranulocytosis constitute a medical emergency and appropriate replacement therapy is usually indicated. It is imperative that such patients are not SUbjected to invasive procedures (e.g. arterial punctures, endotracheal intubation or surgery) until appropriate measures have been taken to elucidate the cause and to correct the circulating cellular deficiency.
Coaglllation Factor Therapy
Bleeding due to congenital or acquired failure of the coagulation system due to multiple or individual factor deficiencies nearly always involves transfusion of stored coagulation factors in one form or another. The recognition and accurate diagnosis of systemic haemostatic failure is of crucial importance, particularly in acute situations, as definitive therapy and factor replacement therapy may significantly effect the outcome. Frequently, complicated tests are required for definitive diagnosis of acquired disorders of the coagulation system, but in many emergency situations, diagnosis and therapy cannot await results of these investigations and action must be taken on the clinical evidence with the minimum of laboratory investigation. Management of congenital bleeding disorders should be centred in specialized haematology departments.
(a) Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIe) with its multiple aetiologies is one of the most important acquired failures of the haemostatic system encountered in Intensive Care Units. The definitive diagnosis may be very difficult as DIe usually occurs in complex clinical situations. Although DIe is a common mechanism of disease and death, and may occur as an "agonal" event, its early diagnosis and management may allow the patient to be supported for hours or days, allowing time for definitive diagnosis and treatment of the underlying inciting disorder. The cause, pathophysiology and management of DIe will not be discussed in this presentation but emphasis will be laid on the consumption phase of the syndrome, where coagulation factor replacement therapy may be of paramount importance. When disseminated intravascular coagulation has progressed to the point of coagulation factor consumption and thrombocytopenia, a grave generalized bleeding disorder may result. Assuming all attempts to remove the initiating event (e.g. infection, trauma, obstetric complication, malignancy) are being undertaken, this bleeding phase should be treated by factor replacement therapy. It is important that either fresh blood or fresh frozen blood products be used, as labile coagulation factors and possibly platelets are required during this phase of the syndrome. The problems of rnicroaggregates, platelet deficiency, rigid red cells, impaired haemoglobin function, low factor V and VIII levels, all mitigate against stored blood being of much value in this syndrome. The success of therapy in the bleeding (consumption) phase of DIe depends on being able to "switch 4.naesthesla and IntensIve Care, Vol. VI, No. 4. November. 1978 off" the coagulation system, irrespective of whether the initiating event has been removed or not. There is some evidence that low inhibitor levels (e.g. antithrombin Ill) may be responsible for perpetuation of the syndrome if the cause persists or resolves slowly. Large volumes of fresh frozen plasma and possibly heparin therapy may be required to gain control.
(b) Massive Blood Transfusion
The haemostatic abnormalities associated with massive blood transfusion are complex, and an area of considerable controversy (Collins 1974 , Hehne et al. 1976 . In most cases the lesion is multifactorial and therapy should be directed at several aspects. When greater than 10 units of stored blood have been used in resuscitation, fresh blood collected in plastic packs is probably the most appropriate therapy if bleeding continues, as it simultaneously corrects clotting factor depletion, thrombocytopenia and volume. In the massive blood loss -transfusion situation the relative importance of coagulation factor depletion, thrombocytopenia, DIC, shock. impaired synthesis and coagulation inhibitor depletion is debatable. The "cookery book" approach, where haematological laboratory results are treated rather than the patient frequently results in the patient "looking good on paper" but continuing to bleed either locally or systemically. Close liaison between the clinician and haematologist is vital. There does appear to be an overlap area where neither can fully explain continuing bleeding.
(c) Liver Disease
Haemorrhage is common in liver disease and laboratory tests of haemostasis are frequently grossly abnormal. Approximately 15% of patients with clinical and laboratory evidence of liver dysfunction have clinical bleeding abnormalities, but 85% of patients with liver disease are said to have at least one abnormality in their tests of bleeding or clotting function, irrespective of the pathology of the hepatic lesion. Most cases of impaired haemostasis in association with liver disease are multifactorial and the prognosis is often influenced by the clinicians assessment of the degree to which the haemostatic mechanism is deranged, and his awareness of the modes of therapy that are available to treat or prevent haemorrhage. Table 3 lists the haemostatic disturbances that may occur in patients with liver disease. When severe hepatocellular failure is present large volumes of factor replacement, in the form of fresh frozen plasma, are usually necessary to control clinical bleeding. The outcome of the haemostatic disturbance rests ultimately with the severity of the liver disease. Most patients with intractable liver failure usually die from bleeding. A realistic approach must be taken to such clinical situations as large volumes of valuable plasma can be wasted in patients where liver function is irretrievably lost. 
(d) Extracorporeal Blood Flow
Haemostatic failure associated with extracorporeal circuits (especially cardiopulmonary bypass) is usually multifactorial (Bick 1976) . Quantitative and qualitative platelet changes, consumption of coagulation factors, excess fibrinolysis and heparin excess may all occur. Fresh blood in plastic packs or platelet concentrates may be needed. Anticipation and close cooperation with blood bank is essential. Blood bank should be kept adequately informed on what is happening, pre-, intra-and post-operatively so problems can be anticipated and efficiently handled. Urgent demands for "shot gun" blood replacement when an originally elective problem has evolved into a complicated haemostasic disturbance are unlikely to result in ideal transfusion therapy for the patient. In recent years homologous blood transfusion has been reduced resulting in improved haemostasis. Intraoperative haemodilution with reinfusion of autologous blood at the conclusion of bypass protects units of blood from damage by the extracorporeal circuit.
COMPLICATIONS OF TRANSFUSION THERAPY
"A frank appraisal of the facts proves that blood transfusion must honestly be regarded as a procedure involving considerable danger and even as potentially lethal" (MaxweII Wintrobe). 1. P. ISBISTER AND R. D. SCURR
Acute Transfusion Reactions
When considering transfusion reactions, most clinicians think in terms of haemolytic complications related to red cell incompatibility. Although this is one of the most dreaded complications it is relatively rare, as red cell compatibility testing is a highly sophisticated procedure. Non haemolytic reactions are more common, many of which are incompletely understood. A recent survey of transfusion reactions revealed that only 1 % were due to red cell incompatibility (Kay 1974) .
It is almost impossible to assess, with accuracy, the frequency of adverse effects of blood transfusion. In many cases the association between blood transfusion and a resultant clinical problem is quite clear, whereas in others, the relationship may not be realized. Table 4 lists some of the clinical presentations of transfusion reactions. 
Fever
Fever is accepted as a common accompaniment of blood transfusion and is usually dismissed lightly by the clinician. However, when the effects of rigors and fever are considered in a seriously ill patient, particularly in terms of increased oxygen consumption, fever should not be considered harmless. Historically, pyrogens were the most common cause of febrile reactions following blood transfusion. These reactions were usually related to pyrogenic material contaminating the container, anticoagulant or giving set. These days most febrile reactions are immunological in origin due to recipient antibodies against leucocytes, or less commonly platelet or plasma proteins. Fever also accompanies red cell destruction whether it be due to incompatibility or poor storage. Clinicians frequently attribute septicaemia to blood transfusion. Such a sequence of events is almost impossible as the normal bacteriocidal activity of blood and subsequent storage renders virtually all blood sterile. Occasionally stored units of blood may yield a growth of psycrophilic organisms (preferring the cold) such as pseudomonads, colitorms and achromobacters. It is these organisms that may multiply when blood is left standing above 4°C, resulting in endotoxin production, citrate consumption and subsequent coagulation and haemolysis of the blood. Transfusion of such blood can be rapidly fatal due to endotoxic shock. If septicaemia does occur following blood transfusion, it is almost certainly related to thrombophlebitis from the intravenous cannula site. Many of the well recognized organisms causing septicaemia cultured from the bottle are almost certainly contaminants introduced at the time of transfusion.
Transfusion induced fever should initially be managed by slowing the rate of infusion and admmistering antipyretics. There is no evidence that antihistamines are of any benefit. If a patient is having rigors the transfusion should be stopped and appropriate investigations undertaken. Recurrent tebrile reactions may be avoided by using leucocyte poor blood.
Pulmonary Oedema
Pulmonary oedema following blood transfusion has traditionally been accepted as due to fluid overload. Although this is usually the case, particularly in elderly anaemic patients, it should be remembered that donor leucoagglutinins (Ward 1970) anaphylactic reactions (Kernoff et al. 1972 ) and probably micro aggregates (I nternational Forum 1977) may also b~ associated with an acute interstitial pulmonary oedema. Patients with severe plasma hyperviscosity may also have pulmonary oedema precipitated by blood transfusion.
Allergic, Anaphylactic and Hypotensive Reactions
Most allergic reactions are probably due to antib:Jdies against immunoglobulins, especially IgA. Occasional reactions may be IgE mediated and probably relates to the blood donor having ingested something to which the recipient is allergic. Acute anaphylactic or anaphylactoid reactions following transfusion of blood components or plasma volume expanders are rare but require immediate recognition and therapy. People congenitally deficient in IgA form anti-IgA antibodies which may be responsible for acute 4naesthesia and Intensive Care. Vol. VI. No. 4. November. 1978 anaphylactic reactions (Pineda et al. 1975) .
It is of paramount importance that hypotension following transfusion of blood components or blood substitutes be rapidly recognized as it may be misinterpreted as further blood loss. Acute haemolytic, anaphylactic and endotoxic reactions and possibly micro aggregates can all be responsible for hypotension following blood transfusion. Any of the plasma volume expanders may also be associated with hypotensive reactions.
There have been several reports in recent years from various parts of the world of vasodilatation and hypotension occurring with plasma protein fractions (Bland et al. 1973 , Torda et al. 1973 , Isbister et al. 1976 , Kaye 1976 ). These reactions have been particularly noted in patients on cardiopulmonary by-pass or during plasmapheresis on blood cell separators. It appears that there are varying concentrations of kinin or kininogen and possibly proteolytic activators in the various plasma protein fractions (Mackay 1962 , Horowitz 1968 , Izaka et al. 1974 , Izaka et al. 1975 , Culliver et al. 1977 . One reason the reactions have been particularly noted during cardiopulmonary by-pass may be related to the exclusion of the lung, one of the main inactivating sites for kin ins. The high incidence of reactions during plasmapheresis is probably related to the rapid infusion rate of these solutions in normovolaemic conscious patients. Not only may vasodilatation and hypotension be deleterious to the exanguinated patient, but hypotension may be misinterpreted as further blood loss and excessive plasma protein fractions given.
The rapid infusion of Haemaccel results in significant histamine release which may manifest as pruritus or urticaria. On rare occasions bronchospasm and hypotension have been noted.
Macrodex may rarely be associated with anaphylactoid reactions, the nature of which has not been fully elucidated. The reaction is not dose related and appears to be immunological in nature, with release of kinins and histamine. Reactions are said to be less frequent in the anaesthetized patient and hypotension in this situation may be the only feature. In the conscious patient, features of kinin release are apprehension, constricting chest pain, back pain, abdominal cramps, flushing and hypotension.
Bleeding
Bleeding may be the first recognized manifestation of a haemolytic transfusion reaction, particularly if the patient is under anaesthesia. Post transfusion thrombocytopenic purpura is a rare complication of blood transfusion. The infusion of large volumes of Dextran have long been recognized to be associated with the development of a haemostatic defect. More recently the mechanism of this defect has been elucidated and it appears that Dextrans induce an acquired Von WiIIebrand's syndrome. If total infusion is less than 1500 ml in 24 hrs bleeding is not usually a problem. The effect of dextran on haemostasis may be used to advantage as prophylaxis against venous thrombosis.
Acute Haemolysis
Rapid intravascular haemolysis or transfusion of haemolyzed blood is an uncommon but potentially lethal condition. Such an event may occur under several circumstances (Table 5 ) . Intravascular haemolysis may manifest itself in several ways. There appears to be an activation of several proteolytic systems (Goldfinger 1977). The complement system is activated by the classical pathway, culminating in red cell destruction. The by-products of the complement sequence have anaphylatoxic (histamine releasing) an.d kinin like activities, which may explain many of the clinical features e.g. apprehension, lumbo-sacral and chest pain, fever, rash, flushing, headache and hypotension (Lopas et al. 1973) . There is good evidence that the kinin system itself is activated with the release of bradykinin. Disseminated intravascular coagulation is a feature in up to 50% of cases. As with several other clinical conditions there appears to be a generalized intravascular proteolysis. The consequence of this will very much depend on the clinical condition of the patient (e.g. fluid balance, shock, renal impairment), the level of inactivators (e.g. antithrombin Ill, kininases, and Cl esterase) and the state of the reticuloendothelial system. This intravascular proteolytic activation is probably precipitated by red cell stroma rather than free haemoglobin. Although haemoglobin may be toxic on the kidney, the development of acute renal failure following intravascular haemolysis is probably dependent on the red cell stroma and associated factors.
Success in managing acute haemolytic transfusion reactions is dependent on rapid recognition and therapy. Following cessation of blood transfusion, the blood volume must be restored rapidly by other means. This is important as the patient was probably volume depleted prior to the blood transfusion and the situation has been aggravated by the incompatable transfusion. Diuresis should be induced with mannitol and/or frusemide accompanied by further intravenous electrolyte solution so as to maintain a high urinary output. Alkalinizing the urine with sodium bicarbonate and diamox may be helpful by increasing the solubility of filtered haemoglobin.
Problems related to the rapid infusion of blood products
It is usually in the clinical context of massive blood loss that blood products are being infused rapidly. Detailed scientific studies have not been possible in such clinical situations and much of the information available on the subject is based on theoretical considerations or anecdotal experiences and "hard data" is difficult to obtain. Expericnce gained from elective exchange transfusion or extracorporeal circulation cannot necessarily be extrapolated to massive blood transfusion, as fresh blood is usually used, normovolaemia is maintained as volume for volume is exchanged, most organs are functioning normally and metabolism is active. Some of the problems related to massive blood transfusion are due directly to rapid infusion of blood products whereas others are due to the "lesion of storage". As most of the patients are critically ill, with multiple problems, we must at least be aware of the possible implications of the rapid infusion of blood products. Rapid infusion through central intravenous lines is potentially hazardous and should be avoided.
(a) Citrate Toxicity
Much has been written about this subject but it is only since the introduction of calcium electrodes that much scientific data has been available. Although ionized calcium drops with rapid citrate infusion, this is usually not a clinical problem in the well perfused, warm patient, with active metabolism, when blood is transfused up to one unit per 5 minutes. Many patients undergoing massive blood transfusion are underperfused, hypothermic with failing organ function and disordered metabolism. All these factors reduce the patients tolerance of the citrate load. Subjective symptoms of hypocalcaemia are not infrequent if carefully sought after (Olson et al. 1977) . The more serious cardiovascular effects are less well understood, but recent data suggests that previous teaching underrating the effects, should be reconsidered (Olinger et al. 1976 ). Coagulation impairment due to hypocalcaemia is exceptionally rare, but it should be remembered that it will not be detected by the conventional tests as decalcified blood is used for the standard coagulation profile.
(b) Hypothermia
It should be standard practice to use efficient blood warmers whenever large volumes of blood products are being infused rapidly.
(c) Vasoactive Substances
The problems with SPPS have already been discussed but other vasoconstrictor and vasodepressor substances may be present in a wide range of blood products. These may be released from degenerating cellular components or due to alterations or activation of plasma proteins. There is good evidence that in vitro storage effects on neutrophils and the cooling, freezing, or lyophilizing of plasma may produce activation of the various proteolytic systems of the blood (Stormorken 1977 , Culliver et al. 1977 , Kaye 1976 , Horowitz et al. 1977 . The implications of these changes in transfusion therapy are not fully understood and it is likely that most recipients are able to rapidly clear such activated substances. There may however be several clinical situations where the rapid infusion of "activated" plasma may lead to cardiovascular changes.
(d) Hyperkalaemia and Acid Base
Disturbances Stored blood may have significantly elevated levels of potassium and low pH. These changes are unlikely to cause problems except in AnaesthesIa and IntensIve Care. Vol. VI, No. 4, November, 1978 patients who already have severe metabolic disturbances or renal impairment. Hypokalaemia may occur as a delayed feature due to K + influx into the transfused red cells, as they repair their metabolism.
(e) Microaggregates
Stored blood contains much debris which includes micro aggregates of intact and broken down platelets, leucocytes and fibrin strands. Frank clot may also be present but is removed by standard 170 p. filters. Microaggregates however range in size from 20 to 200 p. and most of these will pass through the conventional nylon mesh blood transfusion filters. These micro aggregates accumulate from approximately four days of storage and progressively increase in number and size until expiry of the unit (James 1976 ). There has been much discussion in the literature concerning the relationship between micro aggregates and the development of the adult respiratory distress syndrome (James 1976 , Takaori et al. 1977 and whether microfilters have any effect in reducing the incidence or severity of the syndrome. Readers are referred to recent reviews of this subject but the ev1dence at the present time is conflicting (International Forum 1977 , Walker 1978 . Whatever the outcome of this controversy, it must be remembered that most patients who die following massive blood loss, die because of inadequate red cell or volume replacement, and not because of complications of the blood they did receive. However, until this controversy is resolved, it seems reasonable that when large volumes of stored blood are being transfused over short periods of time, that micro filters should be used. The surface mesh filters appear to be the most practical, as they can accommodate high flow rates with gravity and pressure flow, need less frequent changing but have the possible disadvantage of allowing smaller particles through (Kennedy et al. 1977) .
Post Transfusion Jaundice
Jaundice occurring at various times following blood transfusion is relatively common. An acholuric unconjugated hyperbilirubinaemia occurring following blood transfusion is usually the result of an haemolytic transfusion reaction. A more common finding in the seriously ill or post operative patient following blood transfusion is a conjugated hyperbilirubinaemia with bile in the urine (Schmid et al. 1965) . Until recently it has Anaesthesia and Intensive Care, Vol. VI, No. 4, November,1978 been assumed that blood transfusion could not be contributory in this situation. However, it is becoming recognised that in seriously ill patients there may be an intrahepatic cholestasis, the nature of which is sub judice (Elinger 1978) . As a result of this impaired biliary excretion, any increased load of bilirubin will not be effectively handled by the patient and will manifest as a conjugated hyperbilirubinaemia. As a significant proportion of transfused blood, depending on the age, may not survive to circulate in the recipient, the multitransfused patient has to handle a substantial load of bilirubin which can be effectively conjugated but cannot be excreted.
Post Transfusion Hepatitis
Although viral hepatitis is a late complication of blood transfusion, it is probably one of the most hazardous and unsolved complications of blood transfusion (Conrad 1976) . Physicians involved in the administration of blood and blood products should be aware of the current incidence and risks of post transfusion hepatitis . Initial hopes that introduction of the hepatitis B surface antigen screening (Australia Antigen) would prevent post transfusion hepatitis have not been fulfilled. Much of the recent research has concentrated on hepatitis B and the various antigens associated with this disease. The HBs Ag has been clearly associated with many cases of post transfusion hepatitis, but also with chronic persistent hepatitis, chronic active hepatitis, cirrhosis, hepatoma and polyarteritis nodosa. With the introduction of mass screening of blood donors for HBs Ag, only about 10% of post transfusion hepatitis is now due to this agent. Mter exclusion of glandular fever and CMV, markers for other viral hepatitides, such as hepatitis non A non B (hepatitis C) are inadequate and it is difficult to make a definitive diagnosis. It is now recognised that most post transfusion hepatitis is in fact hepatitis C which has a similar incubation period and clinical features to hepatitis B (Blumberg 1977) . No antigenic marker has been identified for hepatitis C but the disease has recently been transmitted to chimpanzees (Alter et al. 1978) . It should be emphasised that most cases of post transfusion hepatitis are asymptomatic and that as many as 25 % of cases are likely to develop chronic liver disease (Seeff et al. 1977 , Koretz et al. 1976 . A definitive diagnosis of post transfusion hepatitis may be difficult to make as differentiation from drug induced hepatitis may be impossible. The incidence of post transfusion hepatitis varies from country to country, but no reliable Australian figures are available. A recent study from the United States indicates a 0.2% unit risk of post transfusion hepatitis . Impaired Reticuloendothelial Function.
The reticuloendothelial system plays an important role in the clearance of bacteria, endotoxins, control of haemostasis and immunological function and possibly in the disseminatlon of malignant tumours. It is well recognised that depression of the reticuloendothelial system may occur in many situations, including post operatively, post haemorrhagic shock, cardio pulmonary by-pass surgery, administration of steriods and possibly following blood transfusion (Wilson et al.) .
There is little doubt that depression of the reticuloendothelial system may significantly effect the outcome of a patients illness. Not only might the patient become susceptible to overwhelming infection or endotoxaemia, but blockade of the reticuloendothelial potentiates the hypercoaguable state. There is some data that indicates that blood transfusion does have an effect in blocking the reticuloendothelial system as demonstrated by delayed clearance of 11 31 aggregated serum albumin (Wilson et al.) . If blood transfusion does have significant effects on reticuloendothelial function, the implications are considerable, particularly as blood is usually being transfused at a time when the patient is most in need of this important defence system of the body.
Sensitization Following Blood Transfusion
Exposure to blood products induces varying degrees of sensitization against any of the cellular components. This may have implications for future transfusion therapy, especially if platelet or granulocyte support is required. Red cell alloimmunisation may result in future haemolytic disease of the newborn. Except for bone marrow, organ transplantation is not adversely effected by blood transfusion, as previously thought.
Laboratory Aspects of Blood Transfusion
Resuscitation and definitive replacement therapy for the exsanguinated patient who continues to bleed requires close liaison between the clinician, the laboratory and central blood bank, in order to make optimum use of facilities available and provide the best transfusion support for the patient. There are not only the logistic problems of supply but also serological considerations relating to massive blood transfusion and urgent cross matching. When blood is required urgently and adequate time is not available for a complete crossmatch, the clinician should be aware of the relative risks. Pressure is frequently exerted on blood bank technologists to make decisions that are clinical in nature. As blood transfusion is becoming a more complicated specialty it is more difficult for the clinician to know what risks are being taken when uncrossmatched or incompletely cross matched blood is being used. All people involved in the collection supply and transfusion of blood should be aware of the links in the chain and the priorities at each point. Blood supply, should not revolve around any particular point (Fig. 1 ). There are many misconceptions in this area of clinical medicine and certain important points should be emphasised. 
(a) What Constitutes an Urgent Cross Match?
It is a common belief that a saline cross match constitutes a satisfactory urgent compatibility test. It should be pointed out that virtually none of the significant haemolytic antibodies outside the ABO blood group system are detected by the saline cross match. The main value of the saline cross match is a final check of ABO compatibility. The non ABO agglutinating antibodies that may be detected by a saline cross match usually react at low temperatures and are of doubtful clinical significance. The most valuable urgent cross match is a short incubation albumin-Coombs' test which will detect most of the clinically significant antibodies. Many hospitals use enzyme cross matches and although this test will pick up many clinically significant antibodies, it is a rather sensitive technique and may lead to over reporting of insignificant incompatible cross matches.
(b) The Use of Uncrossmatched Blood
Group 0 Rh Neg people have long been referred to as "universal donors". It is now well recognised that many Group 0 people have high titre anti-A or anti-B haemolysins in their plasma. Transfusion of these antibodies into A, B or AB recipients may lead to severe intravascular haemolysis. Haemolysin screened o Rh Neg b!ood is kept available by some hospitals for the rare occasions when time does not permit ABO grouping.
If 0 Rh Neg blood is not available and time does not permit grouping of the patient, 0 Rh Positive blood may be the only alternative available for resuscitation. If there has been time to group the patient the correct ABO group should be given. This overcomes the problem of ABO plasma antibodies causing any complications. As mentioned above, the saline cross match is an important double check of ABO compatibility. Most serious haemolytic transfusion reactions are stilI due to ABO incompatibility resulting from clerical or patient identification errors. 0.5% of recipients of uncrossed matched blood may have a clinically significant antibody.
(c) The Group and Hold
Advances in red cell grouping and serum antibody screening techniques have almost eliminated red cell incompatibility as a complication of blood transfusion. It is exceedingly rare for a cross match to be incompatible in the face of a negative antibody screen. This means that if a patient has had an elective blood group and antibody screen, transfusion of group specific uncrossmatched blood is safe. There is a move in many countries to reduce the amount of blood crossmatched for elective operations. A blood group and antibody screen is routinely performed and if blood is required during or following surgery, it can be made available in half an hour or less depending on the urgency of the situation (Fig. 2 ). 'J1his system of elective grouping and screening of recipients reduces the incidence of unnecessary crossmatching and "dating" of blood which is not transfused. If uncrossmatched blood is needed in the presence of a negative antibody screen safety approaches 100%.
CONCLUSION
If the reader of this review has come to the conclusion that blood transfusion has developed into a discipline in its own right, our purpose Anaesthesia and Intensive Care, Vol. VI, No. 4, November, 1978 has been achieved. It is the hope of the authors that clinical blood transfusionists will be able to provide both theoretical and practical support for physicians and anaesthetists involved in the transfusion of blood products. It behoves the clinician to weigh up the advantages and disadvantages of blood component therapy in any particular clinical situation. In so doing he should be in constant consultation with the clinical blood transfusionists. This review has been confined to the transfusion of homologous blood. There is an upsurge of interest in autologous transfusion, elective pre-or intraoperative and "salvage" methods (Messmer 1975 , Brzica et al. 1976 . Autologous blood transfusion helps to overcome many of the supply, storage, and immunological problems.
